Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618209 | 0.96 | POLB (0.47) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL12871625 | 0.82 | GAA (0.53) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL23082833 | 0.79 | POLB (0.50) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL3794341 | 0.77 | POLB (0.47) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL5772957 | 0.76 | POLB (0.55) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL3796773 | 0.74 | CNR2 (0.30) | — | |
| SCHEMBL16739580 | 0.74 | POLB (0.62) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL13684197 | 0.71 | POLB (0.59) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL13693061 | 0.69 | POLB (0.57) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL5067152 | 0.69 | POLB (0.57) | GAAPOLBCYP1A2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | GAA 405/4885POLB 3604/4885CYP1A2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.